Tokyo, JAPAN – Mitsubishi Chemical Medience Corporation (MCM) today announced that the company enters into an exclusive license agreement of Energy Resolved Oxonium Ion Monitoring (Erexim) Technology [PATPEND], jointly-developed by RIKEN (RIKEN) and Shimadzu Corporation (Shimadzu), in glycomics analysis services. By use of Erexim technology, MCM starts up evaluating the usefulness of Glycomics Analysis Services for guiding development and quality management of glycosylated biologics and biosimilars.

Glycomics analysis is essential for research and development of biologics. But up to the present date, it has been hindered from progress due to the lack of actual quantitative technologies. The particular glycans, the sugar chains known as glycosylation bound to proteins, are important to determine the function of resultant glycoprotein. Even minor

structural differences of glycans can significantly affect the efficacy and safety of drugs. So it is important to quantitatively evaluate these structural differences for developing and quality management of glycosylated biologics and biosimilars.

Erexim Technology, jointly-developed by RIKEN and Shimadzu, is the precise analytical technology that is capable of quick and simple analysis for glycan structure using triple quadrupole mass spectrometer. Application of this skill to developing glycosylated biologics and biosimilars can provide drugs with better efficacy and safety. Erexim Technology can also be a global standard for the quality evaluation of lot-to-lot variability.

MCM is the leading company provides nonclinical and clinical operations as drug development support services and has been highly evaluated in the bioanalysis field. Our C- Lab has been accredited by the College of American Pathlogists (CAP) and is the largest laboratory for clinical trials in Japan. And now MCM starts up evaluating the usefulness of glycomics analysis with Erexim technology as a new bioanalysis service.About Mitsubishi Chemical Medience Corporation Mitsubishi Chemical Medience Corporation is a member of the Mitsubishi Chemical Holdings Corporation Group, which is headquartered in Tokyo, Japan. Mitsubishi Chemical Medience is the first company in Japan to establish a business style that combines clinical

and diagnostic laboratory testing services with in vitro diagnostics (IVD) and pharmaceutical development support. One of Mitsubishi Chemical Medience’s primary business areas is their IVD business, which includes the development, sale, export,and import of in vitro diagnostic reagents and instruments. Mitsubishi Chemical Medience’s globally accepted PATHFAST system, a rapid point-of-care immunochemistry analyzer, has been exported to more than 40 countries. Throughout almost five decades of IVD business, customers in various chemical and diagnostic industry segments have come to trust and rely on Mitsubishi Chemical Medience’s competence and strength, as represented by the superior quality of their products and customized solutions. To learn more, visit the company’s website at https://www.medience.co.jp/english/index.html

About RIKEN

RIKEN is Japan’s largest comprehensive research institution renowned for high-quality research in a diverse range of scientific disciplines. Founded in 1917 as a private research foundation in Tokyo, RIKEN has grown rapidly in size and scope, today encompassing a network of world-class research centers and institutes across Japan.

About Shimadzu Corporation

Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation built on the foundation of contributing to society through science and technology. Shimadzu maintains a global network of sales, service, technical support and applications centers on six continents, and has established long-term relationships with a host of highly trained distributors located in over 100 countries.